We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Urine-Based Test Detects Prostate Cancers

By LabMedica International staff writers
Posted on 04 Sep 2025

Prostate cancer is one of the leading causes of death in men in the US and is usually detected through prostate-specific antigen (PSA) blood tests. More...

However, PSA is not very specific, meaning many men undergo invasive biopsies that are often negative and carry risks. In addition, PSA testing can lead to overtreatment of low-grade cancers. Now, researchers have identified biomarkers in urine that can accurately detect prostate cancer and reduce unnecessary procedures.

A team at Johns Hopkins Medicine (Baltimore, MD, USA) working with several partner institutions has developed a urine-based test using three biomarkers: TTC3, H4C5, and EPCAM. These markers were present in patients with prostate cancer but nearly absent after prostate-removal surgery, confirming their origin in prostate tissue. The test analyzes RNA extracted from prostate cells shed in urine using RNA sequencing, qPCR, and immunohistochemistry to validate expression patterns.

In development and validation studies using over 1,300 urine specimens, the test achieved an area under the curve (AUC) of 0.92, correctly identifying prostate cancer 91% of the time and ruling out non-cancer cases 84% of the time. The results, published in eBioMedicine, show that it also distinguished prostate cancer from benign conditions such as BPH and prostatitis, outperforming PCA3.

The test showed strong diagnostic accuracy even in PSA-negative patients, maintaining performance of 78.6% and 85.7% across cohorts. By distinguishing cancer from benign conditions and detecting cases with normal PSA levels, it could complement or even surpass PSA screening. Researchers plan to further develop the assay for clinical use, explore its integration with PSA as a “super PSA,” and test it independently at other institutions before broader deployment.

“This new biomarker panel offers a promising, sensitive and specific, noninvasive diagnostic test for prostate cancer,” said Ranjan Perera, Ph.D., senior study author. “It has the potential to accurately detect prostate cancer, reduce unnecessary biopsies, improve diagnostic accuracy in PSA-negative patients, and serve as the foundation for both laboratory-developed and in vitro diagnostic assays.”

Related Links:
Johns Hopkins Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: The partnership between OGT and QIAGEN unlocks a complete sample to report workflow for SureSeq NGS panels (Photo courtesy of OGT)

Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

In clinical research, next-generation sequencing (NGS) panels provide essential insights for genetic analysis, but many laboratories face challenges in transforming raw sequencing data into clinically... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.